August 12, 2015 / 12:54 PM / 2 years ago

BRIEF-Roche says venetoclax met primary endpoint in phase II trial

Aug 12 (Reuters) - Roche Holding Ag

* Says pivotal phase ii study of investigational medicine venetoclax met primary endpoint in a hard-to-treat type of chronic lymphocytic leukemia Source text for Eikon: Further company coverage: (Reporting By Zurich Slot)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below